Dodd I, Mossakowska D E, Camilleri P, Haran M, Hensley P, Lawlor E J, McBay D L, Pindar W, Smith R A
Department of Protein Chemistry, SmithKline Beecham Pharmaceuticals, Epsom, Surrey, United Kingdom.
Protein Expr Purif. 1995 Dec;6(6):727-36. doi: 10.1006/prep.1995.0003.
We have developed a simple expression, isolation, and folding protocol for an SCR oligomer comprising the first three SCRs of complement receptor Type 1 (C3b/C4b receptor, CD35). A T7 RNA polymerase expression system in Escherichia coli was used to express the oligomer as inclusion bodies. The oligomer was recovered from solubilized inclusion bodies using batch adsorption on SP-Sepharose. The oligomer was folded by one-step dilution in 20 mM ethanolamine/1 mM EDTA supplemented with 1 mM GSH/0.5 mM GSSG. The folded material was processed to a concentrated (> 20 mg/ml), usable product of greater than 98% purity using a combination of ultrafiltration, ammonium sulfate treatment, hydrophobic interaction, and size-exclusion chromatography. The yield of folded material varied between 6 and 15 mg/liter culture. The oxidation states of the 12 cysteine residues in SCR(1-3) were identified by HPLC of peptide fragments from a tryptic digest using dual UV/fluorescence detection, collection of selected peaks, and N-terminal sequencing. This methodology confirmed the expected location of disulfide bridges. Equilibrium and velocity sedimentation studies are interpreted in terms of a single sedimenting species with molecular weights of 21,629 and 21,063 by these respective techniques. These values compare to the predicted molecular weight, from amino acid composition, of 21,817. The hydrodynamic properties of the molecule indicate that it is asymmetric with an axial ratio of 1:5.2 or equivalent dimensions of 21 x 110 A. SCR(1-3) has an unusual CD spectrum exhibiting a broad maximum at 220-230 nm and a minimum at 190 nm. There was little evidence of classical secondary structure. The product exhibited concentration-dependent inhibition of complement-mediated lysis of sensitized sheep red blood cells.
我们已经开发出一种针对包含补体1型受体(C3b/C4b受体,CD35)前三个短共识重复序列(SCR)的SCR寡聚体的简单表达、分离和折叠方案。利用大肠杆菌中的T7 RNA聚合酶表达系统将该寡聚体表达为包涵体。通过在SP-琼脂糖凝胶上进行批量吸附,从溶解的包涵体中回收该寡聚体。通过在补充有1 mM还原型谷胱甘肽/0.5 mM氧化型谷胱甘肽的20 mM乙醇胺/1 mM乙二胺四乙酸中一步稀释来折叠该寡聚体。使用超滤、硫酸铵处理、疏水相互作用和尺寸排阻色谱相结合的方法,将折叠后的材料加工成浓度大于20 mg/ml、纯度大于98%的可用产品。折叠材料的产量在每升培养物6至15 mg之间变化。通过使用双紫外/荧光检测、收集选定峰和N端测序,对胰蛋白酶消化产生的肽片段进行高效液相色谱分析,确定了SCR(1-3)中12个半胱氨酸残基的氧化状态。该方法证实了二硫键的预期位置。平衡沉降和速度沉降研究通过这些各自的技术解释为分子量分别为21,629和21,063的单一沉降物种。这些值与根据氨基酸组成预测的分子量21,817相比。该分子的流体动力学性质表明它是不对称的,轴比为1:5.2或等效尺寸为21 x 110 Å。SCR(1-3)具有不寻常的圆二色光谱,在220 - 230 nm处有一个宽峰,在190 nm处有一个最小值。几乎没有经典二级结构的证据。该产品表现出对补体介导的致敏绵羊红细胞裂解的浓度依赖性抑制作用。